

# Yun Fan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1319473/publications.pdf>

Version: 2024-02-01

31  
papers

2,899  
citations

759233

12  
h-index

477307

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3850  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347
2	High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 121.	8.6	69
3	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer: KEYNOTE-042 China Study. <i>International Journal of Cancer</i> , 2021, 148, 2313-2320.	5.1	60
4	Development of a serum miRNA panel for detection of early stage non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25036-25042.	7.1	54
5	Immune microenvironment features and efficacy of PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions. <i>Thoracic Cancer</i> , 2021, 12, 218-226.	1.9	44
6	Improving the Accuracy of Mesothelioma Diagnosis in China. <i>Journal of Thoracic Oncology</i> , 2017, 12, 714-723.	1.1	43
7	Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 526-539.	7.0	39
8	KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. <i>Frontiers in Oncology</i> , 2021, 11, 672612.	2.8	38
9	Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019, 10, 5076.	12.8	30
10	Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 480.	2.8	28
11	Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. <i>Cancer</i> , 2020, 126, 840-849.	4.1	24
12	Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases. <i>Lung Cancer</i> , 2018, 125, 8-13.	2.0	17
13	Efficacy of PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China. <i>Thoracic Cancer</i> , 2021, 12, 3019-3031.	1.9	12
14	Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. <i>International Journal of Cancer</i> , 2021, 149, 1121-1128.	5.1	11
15	Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8837-8844.	2.0	10
16	Clinical Relevance of PD-L1 Expression and CD8+ T Cells Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 683432.	2.8	9
17	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720044.	2.8	9
18	The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 2930-2940.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1959-1963.	1.1	7
20	Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases. <i>Molecular Brain</i> , 2021, 14, 176.	2.6	7
21	Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2291-2300.	1.9	7
22	A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary. <i>Journal of Translational Medicine</i> , 2022, 20, 158.	4.4	6
23	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 4511-4525.	2.8	6
24	Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5719-5726.	2.0	5
25	Progress on treatment of MET signaling pathway in non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1450-1458.	2.2	4
26	Towards customized cancer vaccines: a promising field in personalized cancer medicine. <i>Expert Review of Vaccines</i> , 2021, 20, 545-557.	4.4	2
27	The prognostic role of a novel TP53 mutation classifier in resectable esophageal squamous-cell carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, e14749-e14749.	1.6	1
28	ASO Author Reflection: The TME-Related Gene AIF1 Signature Predicts Esophageal Carcinoma Prognosis. <i>Annals of Surgical Oncology</i> , 2022, 29, 2941-2941.	1.5	1
29	Abstract CT555: Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study. <i>Cancer Research</i> , 2022, 82, CT555-CT555.	0.9	0
30	Abstract CT554: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study. <i>Cancer Research</i> , 2022, 82, CT554-CT554.	0.9	0
31	Abstract CT553: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): Subanalysis from the RATIONALE-303 phase 3 randomized clinical study. <i>Cancer Research</i> , 2022, 82, CT553-CT553.	0.9	0